Cardiac and peripheral adjustments induced by early exercise training intervention were associated with autonomic improvement in infarcted rats: role in functional capacity and mortality

Carregando...
Imagem de Miniatura
Citações na Scopus
47
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS
Autores
RODRIGUES, Bruno
ROSA, Kaleizu Teodoro
LOUREIRO, Tatiana Carolina Alba
MEDEIROS, Alessandra
CURI, Rui
BRUM, Patricia Chakur
LACCHINI, Silvia
MONTANO, Nicola
Citação
EUROPEAN HEART JOURNAL, v.32, n.7, p.904-912, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Aims To test the effects of early exercise training (ET) on left ventricular (LV) and autonomic functions, haemodynamics, tissues blood flows (BFs), maximal oxygen consumption (VO2 max), and mortality after myocardial infarction (MI) in rats. Methods and results Male Wistar rats were divided into: control (C), sedentary-infarcted (SI), and trained-infarcted (TI). One week after MI, TI group underwent an ET protocol (90 days, 50-70% VO2 max). Left ventricular function was evaluated noninvasively and invasively. Baroreflex sensitivity, heart rate variability, and pulse interval were measured. Cardiac output (CO) and regional BFs were determined using coloured microspheres. Infarcted area was reduced in TI (19 +/- 6%) compared with SI (34 +/- 5%) after ET. Exercise training improved the LV and autonomic functions, the CO and regional BF changes induced by MI, as well as increased SERCA2 expression and mRNA vascular endothelial growth factor levels. These changes brought about by ET resulted in mortality rate reduction in the TI (13%) group compared with the SI (54%) group. Conclusion Early aerobic ET reduced cardiac and peripheral dysfunctions and preserved cardiovascular autonomic control after MI in trained rats. Consequently, these ET-induced changes resulted in improved functional capacity and survival after MI.
Palavras-chave
Myocardial infarction, Exercise training, Cardiac function, Autonomic function, Blood flow
Referências
  1. Liao L, 2008, PHARMACOECONOMICS, V26, P447, DOI 10.2165/00019053-200826060-00001
  2. Knox AJ, 2001, FASEB J, V15, P2480, DOI 10.1096/fj.01-0256com
  3. Brown DA, 2003, J APPL PHYSIOL, V95, P2510, DOI 10.1152/japplphysiol.00487.2003
  4. Freimann S, 2005, J AM COLL CARDIOL, V45, P931, DOI 10.1016/j.jacc.2004.11.052
  5. WANG W, 1991, CIRC RES, V68, P1294
  6. De Angelis K, 2005, BRAZ J MED BIOL RES, V38, P119, DOI 10.1590/S0100-879X2005000100018
  7. Souza SBC, 2007, HYPERTENSION, V50, P786, DOI 10.1161/HYPERTENSIONAHA.107.095000
  8. COHN JN, 1993, CIRCULATION, V87, P5
  9. Negrao CE, 2008, HEART FAIL REV, V13, P51, DOI 10.1007/s10741-007-9057-7
  10. Xu XH, 2008, J MOL CELL CARDIOL, V44, P114, DOI 10.1016/j.yjmcc.2007.10.004
  11. Malliani A, 2002, HYPERTENSION, V39, P63, DOI 10.1161/hy0102.099200
  12. Medeiros A, 2008, J APPL PHYSIOL, V104, P103, DOI 10.1152/japplphysiol.00493.2007
  13. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  14. Milkiewicz M, 2006, J PHYSIOL-LONDON, V577, P671, DOI 10.1113/jphysiol.2006.113357
  15. Rondon E, 2006, AM J PHYSIOL-HEART C, V291, pH2801, DOI 10.1152/ajpheart.01352.2005
  16. Mostarda C, 2009, AUTON NEUROSCI-BASIC, V145, P11, DOI 10.1016/j.autneu.2008.10.010
  17. Guzzetti S, 2005, EUR HEART J, V26, P357, DOI 10.1093/eurheartj/ehi067
  18. Nozawa E, 2006, BRAZ J MED BIOL RES, V39, P687, DOI 10.1590/S0100-879X2006000500016
  19. SULLIVAN MJ, 1989, CIRCULATION, V79, P324
  20. Flynn KE, 2009, JAMA-J AM MED ASSOC, V301, P1451, DOI 10.1001/jama.2009.457
  21. Shephard RJ, 1999, CIRCULATION, V99, P963
  22. Harthmann AD, 2007, AUTON NEUROSCI-BASIC, V133, P115, DOI 10.1016/j.autneu.2006.10.004
  23. MCELROY CL, 1978, CIRCULATION, V57, P958
  24. BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
  25. KIILAVUORI K, 1995, EUR HEART J, V16, P490
  26. de Tombe PP, 1998, CARDIOVASC RES, V37, P367, DOI 10.1016/S0008-6363(97)00275-7
  27. Portes LA, 2009, CLIN EXP PHARMACOL P, V36, P394, DOI 10.1111/j.1440-1681.2008.05070.x
  28. Lenk K, 2009, EUR J HEART FAIL, V11, P342, DOI 10.1093/eurjhf/hfp020
  29. Braga LMGD, 2008, CLIN EXP PHARMACOL P, V35, P113, DOI 10.1111/j.1440-1681.2007.04820.x
  30. FERGUSON DW, 1992, AM J CARDIOL, V69, P523, DOI 10.1016/0002-9149(92)90998-E
  31. Yamashita N, 1999, J EXP MED, V189, P1699, DOI 10.1084/jem.189.11.1699
  32. Braga LMGD, 2008, J BIOMED SCI, V15, P365, DOI 10.1007/s11373-008-9237-z
  33. CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
  34. COATS AJS, 1992, CIRCULATION, V85, P2119
  35. Esler M, 2000, Heart Fail Rev, V5, P17
  36. Giannuzzi P, 1997, CIRCULATION, V96, P1790
  37. Iellamo F, 2000, CIRCULATION, V102, P2588
  38. Irigoyen MC, 2005, HYPERTENSION, V46, P998, DOI 10.1161/01.HYP.0000176238.90688.6b
  39. La Rovere MT, 1998, LANCET, V351, P478
  40. Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
  41. Rodrigues B, 2007, CARDIOVASC DIABETOL, V6, DOI 10.1186/1475-2840-6-38
  42. Wichi R, 2007, CARDIOVASC DIABETOL, V26, P6
  43. Wu GF, 2009, AM J PHYSIOL-HEART C, V296, pH389, DOI 10.1152/ajpheart.01393.2007
  44. Yamashita N, 2001, HEART, V85, P331, DOI 10.1136/heart.85.3.331